Phase 1 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have read and signed a consent form before any study procedures begin
• People who have been surgically staged with Stage IIIC endometrial cancer (of any tissue type), confirmed by pathology, who are eligible for follow-up treatment combining radiation and chemotherapy after surgery (surgery is defined as full removal of the uterus plus assessment of lymph nodes)
• People who enrolled within 8 weeks of surgery and started treatment within 10 weeks of surgery
• People aged 18 or older
• People who are fully active or have only minor restrictions in physical activity, as measured by a standard medical scale called ECOG (score of 0 or 1)
• People whose blood counts are at adequate levels within 14 days before enrolling — including haemoglobin, platelets, and a type of white blood cell called neutrophils
• People whose kidneys are functioning adequately, based on blood tests within 14 days before enrolling
• People whose liver is functioning adequately, based on blood tests within 14 days before enrolling (people with a condition called Gilbert's disease may still be eligible — confirm with trial site)
• People whose blood clotting measures are within acceptable ranges within 14 days before enrolling, including those on blood thinners if their levels are stable within the intended treatment range
• People who have had, or currently have, another cancer whose history or treatment is unlikely to interfere with this trial's safety or results (for example, a common type of non-melanoma skin cancer)

Who may not be able to join:

• People who have not yet recovered from side effects of previous radiation, major surgery, or chemotherapy
• People who had surgery less than 3 weeks before starting trial treatment, or who received another experimental treatment less than 4 weeks (or less than 5 half-lives of that agent, whichever is shorter) before starting trial treatment
• People who have previously received certain types of immunotherapy drugs that target PD-1, PD-L1, or CTLA-4 pathways
• People who have had a severe allergic reaction to a type of drug called a monoclonal antibody, or specifically to dostarlimab or its ingredients
• People with an active autoimmune disease, or a history of one that could come back and affect vital organ function or require immune-suppressing treatment — this includes conditions such as multiple sclerosis, lupus, inflammatory bowel disease, Guillain-Barré syndrome, myasthenia gravis, scleroderma, and certain severe skin reactions
• People with a history of a lung condition called interstitial lung disease, or inflammation of the lungs not caused by infection (except if caused by radiation treatment)
• People diagnosed with a weakened immune system, or who have been taking daily steroid or immune-suppressing medications within 7 days before enrolling (certain limited exceptions may apply — confirm with trial site)
• People who have received a live vaccine within 30 days of starting trial treatment
• People with significant known liver disease, including active hepatitis, cirrhosis, or a confirmed hepatitis B or C infection
• People with serious uncontrolled illnesses such as active infections, heart problems, unstable angina, irregular heart rhythms, or mental health or social circumstances that would make it difficult to follow the trial requirements
• People who have received specific prohibited medications listed in the trial protocol
• People with cancer that has spread to the membranes surrounding the brain or spinal cord, or who have symptoms from cancer spread to the brain (people with brain involvement that is not causing symptoms and who are off certain medications for at least 7 days may still be eligible — confirm with trial site)
• People known to be living with HIV
• Women who are able to become pregnant and have not had a permanent surgical procedure to prevent pregnancy

Important: Always verify eligibility with the trial site directly before applying.